Is BLCM stock a buy or sell?
According to 3 analysts, the average rating for BLCM stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 210.34% from the latest price.
When did BLCM raise $101 million?
(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.
When does Bellicum Pharmaceuticals Inc watchlistcreateblcmalert blcmus close?
Bellicum Pharmaceuticals Inc. WatchlistCreateBLCMAlert BLCMUS Closed Last Updated: Jan 20, 2022 3:59 p.m. ESTDelayed quote
Should I buy or sell Bellicum Pharmaceuticals stock right now?
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are cur...
What is Bellicum Pharmaceuticals' stock price forecast for 2022?
1 brokers have issued 1-year price objectives for Bellicum Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they pre...
How has Bellicum Pharmaceuticals' stock performed in 2022?
Bellicum Pharmaceuticals' stock was trading at $1.49 on January 1st, 2022. Since then, BLCM stock has decreased by 18.1% and is now trading at $1.2...
When is Bellicum Pharmaceuticals' next earnings date?
Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecas...
How were Bellicum Pharmaceuticals' earnings last quarter?
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its quarterly earnings results on Thursday, March, 24th. The biopharmaceutical company report...
When did Bellicum Pharmaceuticals' stock split? How did Bellicum Pharmaceuticals' stock split work?
Shares of Bellicum Pharmaceuticals reverse split on the morning of Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday,...
Who are Bellicum Pharmaceuticals' key executives?
Bellicum Pharmaceuticals' management team includes the following people: Mr. Richard A. Fair , Pres, CEO & Director (Age 53, Pay $915.28k) Ms. C...
Who are some of Bellicum Pharmaceuticals' key competitors?
Some companies that are related to Bellicum Pharmaceuticals include Ampio Pharmaceuticals (AMPE) , Ampio Pharmaceuticals (AMPE) , Alimera Scienc...
What other stocks do shareholders of Bellicum Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead P...
When will Bellicum Pharmaceuticals release its earnings?
How much does Bellicum Pharmaceuticals make?
Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Bellicum Pharmaceuticals.
About BLCM
How much money does Bellicum Pharmaceuticals make? Bellicum Pharmaceuticals has a market capitalization of $26.46 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-7,720,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis.
Analyst Forecast
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally.
News
According to 3 analysts, the average rating for BLCM stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 223.74% from the latest price.
Ideas
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair,...
Profile
All, BLCM great technicals. Add alerts / volume alerts wait for breakout +1 candle. Float: 5M Shares Outstanding: 7.9M Inst Ownership: 27%
Is BLCM upside or downside?
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.
Is Bellicum stock a sell signal?
Wells Fargo & Company does not see either upside or downside right now giving BLCM "Overweight - Equal Weight" on their last update on October 30, 2020. The price target was set to $4.50 .
